Key Financials Snapshot

TTM · Consolidated · ₹ in Cr
Market Cap
₹453 Cr.
Stock P/E
-4.7
P/B
-2.9
Current Price
₹298.2
Book Value
₹ -103.8
Face Value
10
52W High
₹476.2
52W Low
₹ 225
Dividend Yield
0%

Kaya Overview

Business

Kaya Ltd. is an Indian company primarily engaged in providing specialized skincare, haircare, and body contouring services through its chain of clinics. It offers a range of aesthetic dermatological solutions, anti-aging treatments, laser hair reduction, hair transplant, acne treatments, and various beauty therapies. Kaya operates on a service-led business model, charging customers for consultations, procedures, and treatment packages. It also generates revenue from the sale of its proprietary skincare and haircare products.

Revenue Mix

Kaya Ltd. primarily operates in two segments: Services and Products. While specific detailed revenue contribution percentages are not consistently broken down publicly, the majority of its revenue typically comes from its service offerings (aesthetic treatments, consultations, procedures) delivered through its clinics. Product sales, including its Kaya-branded dermatological products, contribute a smaller but significant portion of overall revenue.

Industry

Kaya operates in the fragmented but growing Indian aesthetic dermatology and healthcare services industry. This industry includes large chains, independent dermatologist clinics, multi-specialty hospitals with dermatology departments, and smaller beauty parlors offering some aesthetic services. Kaya is positioned as a premium player focusing on science-backed solutions and medical expertise. It competes with other organized chains like VLCC, Oliva Skin & Hair Clinic, and numerous local and regional players, differentiating itself through its doctor-led approach and standardized protocols.

MOAT

Kaya's competitive advantages include:

Brand Recognition: Established brand name in the Indian aesthetic dermatology space, associated with quality and medical expertise.

Clinic Network & Scale: A significant footprint of clinics across major Indian cities provides accessibility and leverages brand presence.

Medical Professionals: Emphasizes doctor-led treatments and standardized protocols, building trust and perceived quality.

Proprietary Products: Development and sale of its own skincare and haircare products complement its service offerings and build brand loyalty.

Growth Drivers

Rising Disposable Incomes: Increasing affluence among the Indian middle and upper classes leads to higher discretionary spending on appearance and wellness.

Growing Awareness & Acceptance: Increasing media exposure and social influence are reducing the stigma associated with cosmetic procedures and driving demand.

Expansion into Tier 2/3 Cities: Untapped potential in smaller cities presents opportunities for clinic expansion and market penetration.

Technological Advancements: Adoption of new, effective, and less invasive aesthetic technologies can attract more customers.

Focus on Anti-Aging: The aging population and desire for youthful appearance continue to fuel demand for anti-aging treatments.

Risks

Intense Competition: Highly fragmented market with numerous local and national players, leading to pricing pressures.

Discretionary Spending Nature: Demand for services is sensitive to economic downturns as they are often considered non-essential.

Reputational Risk: Any adverse incident or customer dissatisfaction can severely impact brand trust and business.

Talent Retention: High attrition rates for skilled dermatologists and therapists can affect service quality and operational costs.

Regulatory Changes: Potential for increased regulation in the aesthetic medicine sector regarding procedures, equipment, and product claims.

Management & Ownership

Kaya Ltd. was initially conceptualized and promoted by the Marico Group (led by Harsh Mariwala), a prominent Indian FMCG conglomerate. While Kaya was subsequently demerged, the promoter group (Mariwala family entities) continues to hold a significant stake, indicating their long-term commitment. Management consists of experienced professionals in the retail and healthcare sectors, focusing on strategic expansion and operational efficiency. The ownership structure includes the promoter group, institutional investors, and public shareholders.

Outlook

Kaya Ltd. is positioned in a growing market driven by increasing consumer awareness and spending on aesthetics. Its established brand and clinic network provide a solid foundation for growth, potentially benefiting from market expansion and premiumization trends. However, the company faces significant challenges from intense competition, the discretionary nature of its services making it susceptible to economic cycles, and the need to continuously innovate and maintain high service standards. Sustained growth will depend on effective market penetration, efficient operational management, and the ability to differentiate its offerings in a crowded market.

Kaya Share Price

Live · BSE / NSE · Inception: 2003
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Consolidated · annual

Kaya Quarterly Results

#(Fig in Cr.) Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
Net Sales 54 52 52 53 58 55 53 54 60 56
Other Income 1 2 11 1 1 4 1 4 2 2
Total Income 55 54 62 53 59 59 53 58 62 58
Total Expenditure 44 117 46 47 53 53 49 57 71 68
Operating Profit 12 -64 16 6 6 6 4 1 -10 -11
Interest 7 7 7 8 8 8 8 9 9 9
Depreciation 9 9 9 9 10 9 10 11 12 12
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 -5 4
Profit Before Tax -4 -79 0 -11 -11 -11 -14 -19 -36 -28
Provision for Tax 0 0 0 0 0 0 0 0 0 0
Profit After Tax -4 -79 0 -11 -11 -11 -14 -19 -36 -28
Adjustments -5 -20 103 -5 15 4 0 0 -0 0
Profit After Adjustments -9 -99 103 -16 4 -7 -14 -19 -36 -28
Adjusted Earnings Per Share -6.9 -75.9 78.6 -12 2.8 -5.4 -10.8 -12.4 -23.4 -18.3

Kaya Profit & Loss

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Net Sales 370 409 400 421 393 275 324 377 205 217 222 223
Other Income 12 11 10 4 9 15 12 5 5 17 9 9
Total Income 382 420 410 425 402 290 336 381 210 234 231 231
Total Expenditure 352 425 398 406 338 248 297 363 174 198 232 245
Operating Profit 30 -4 12 19 64 42 39 19 36 37 -1 -16
Interest 4 5 7 9 22 19 21 42 27 32 38 35
Depreciation 17 20 24 29 75 60 86 93 102 38 56 45
Exceptional Income / Expenses 0 0 0 0 0 0 0 0 0 0 -1 -1
Profit Before Tax 9 -30 -19 -19 -33 -37 -68 -116 -94 -33 -96 -97
Provision for Tax 0 -3 -0 -6 21 0 0 0 0 0 0 0
Profit After Tax 9 -27 -19 -14 -54 -37 -68 -116 -94 -33 -96 -97
Adjustments -0 -2 -2 -2 -0 -1 -1 -0 -35 117 0 0
Profit After Adjustments 9 -29 -21 -16 -54 -38 -69 -116 -129 84 -96 -97
Adjusted Earnings Per Share 6.8 -22.2 -16.2 -12.2 -41.7 -29.1 -52.7 -89.2 -98.9 63.9 -63.3 -64.9

Kaya Balance Sheet

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Shareholder's Funds 251 229 210 158 82 54 -2 -104 -227 -139 -153
Minority's Interest 0 2 2 1 1 0 1 1 -0 0 0
Borrowings 0 19 14 19 22 29 79 142 141 144 149
Other Non-Current Liabilities 18 -14 -12 -9 119 103 88 82 95 90 109
Total Current Liabilities 142 190 137 180 189 182 196 249 286 142 172
Total Liabilities 412 425 351 349 413 368 361 370 296 237 278
Fixed Assets 149 193 201 206 303 279 240 217 174 158 193
Other Non-Current Assets 32 46 30 29 15 12 16 11 20 14 13
Total Current Assets 231 187 120 115 95 78 106 143 102 66 72
Total Assets 412 425 351 349 413 368 361 370 296 237 278

Kaya Cash Flow

#(Fig in Cr.) Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Opening Cash & Cash Equivalents 28 27 14 20 19 7 12 20 25 18 7
Cash Flow from Operating Activities 5 -8 -12 22 47 32 30 63 39 1 21
Cash Flow from Investing Activities -6 -42 24 -28 -12 4 -35 -40 -9 25 -63
Cash Flow from Financing Activities -0 33 -7 5 -47 -31 12 -18 -38 -37 37
Net Cash Inflow / Outflow -2 -16 6 -1 -12 5 7 5 -7 -11 -6
Closing Cash & Cash Equivalent 28 14 20 19 7 12 20 25 18 7 1

Kaya Ratios

# Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Earnings Per Share (Rs) 6.82 -22.23 -16.22 -12.22 -41.66 -29.1 -52.69 -89.15 -98.91 63.89 -63.32
CEPS(Rs) 20 -5.54 4.14 11.74 16.19 17.4 13.75 -17.58 6.27 3.26 -26.6
DPS(Rs) 0 0 0 0 0 0 0 0 0 0 0
Book NAV/Share(Rs) 194.12 174.73 159.66 119.02 60.61 41.7 -2.17 -81.58 -174.93 -106.61 -103.8
Core EBITDA Margin(%) 4.78 -3.87 0.56 3.56 14.15 9.8 8.32 3.73 15.08 9.04 -4.48
EBIT Margin(%) 3.57 -5.99 -3.12 -2.36 -2.8 -6.7 -14.57 -19.84 -32.34 -0.44 -26.29
Pre Tax Margin(%) 2.39 -7.29 -4.82 -4.59 -8.4 -13.61 -20.98 -30.86 -45.68 -15.36 -43.23
PAT Margin (%) 2.39 -6.66 -4.72 -3.27 -13.76 -13.61 -20.98 -30.86 -45.68 -15.36 -43.23
Cash Profit Margin (%) 6.97 -1.76 1.35 3.64 5.38 8.27 5.55 -6.1 3.99 1.97 -18.16
ROA(%) 2.24 -6.51 -4.87 -3.93 -14.21 -9.58 -18.64 -31.81 -28.17 -12.54 -37.37
ROE(%) 3.76 -11.41 -8.68 -7.57 -46.11 -55.98 -263.21 0 0 0 0
ROCE(%) 5.43 -9.62 -5.06 -4.65 -7.24 -18.27 -53.94 -121.62 0 0 -776.46
Receivable days 0.95 1.57 2.63 3.96 4.89 5.61 4.02 3.57 6.64 5.07 2.18
Inventory Days 42.64 45.91 42.46 37.46 36.76 42.24 30.75 27.33 51.68 45.69 37.64
Payable days 371.38 355.46 1585.5 1523.06 1058.8 1518.93 1829.08 1177.87 1305.49 763.48 429.39
PER(x) 126.22 0 0 0 0 0 0 0 0 3.65 0
Price/Book(x) 4.44 4.46 6.54 6.01 1.84 7.11 -161.21 -3.1 -1.79 -2.19 -2.3
Dividend Yield(%) 0 0 0 0 0 0 0 0 0 0 0
EV/Net Sales(x) 2.93 2.51 3.41 2.26 0.43 1.49 1.6 1.11 2.78 2.04 2.35
EV/Core EBITDA(x) 35.93 -229.92 115.84 49.7 2.61 9.83 13.37 22.59 16.01 12.06 -414.33
Net Sales Growth(%) 11.32 10.59 -2.12 5.12 -6.57 -30.07 17.82 16.29 -45.54 5.84 2.44
EBIT Growth(%) -62.99 -285.89 48.99 20.42 -10.61 -67.36 -156.16 -58.39 11.23 98.55 -5979.9
PAT Growth(%) -72.13 -407.73 30.63 27.27 -293.44 30.86 -81.66 -71.08 19.38 64.4 -188.22
EPS Growth(%) 0 -425.87 27.04 24.66 -240.91 30.15 -81.09 -69.19 -10.95 164.59 -199.12
Debt/Equity(x) 0 0.13 0.12 0.22 0.37 0.66 -30.33 -1.33 -0.78 -1.03 -1.04
Current Ratio(x) 1.62 0.98 0.87 0.64 0.5 0.43 0.54 0.57 0.36 0.46 0.42
Quick Ratio(x) 1.25 0.72 0.56 0.4 0.31 0.28 0.4 0.45 0.26 0.28 0.3
Interest Cover(x) 3.04 -4.64 -1.84 -1.06 -0.5 -0.97 -2.27 -1.8 -2.42 -0.03 -1.55
Total Debt/Mcap(x) 0 0.03 0.02 0.04 0.2 0.09 0.19 0.43 0.43 0.47 0.45

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +2% -16% -4% -5%
Operating Profit CAGR -103% 0% 0% 0%
PAT CAGR — — — 0%
Share Price CAGR -33% -5% -8% -10%
ROE Average 0% 0% -53% -35%
ROCE Average -776% -259% -190% -90%

Kaya Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 51.43 %
FII 0.71 %
DII (MF + Insurance) 2.99 %
Public (retail) 44.88 %
# Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 59.7959.7959.6459.6459.6459.6451.4351.4351.4351.43
FII 0.741.241.271.271.50.950.630.630.680.71
DII 1.973.533.613.371.712.092.532.792.952.99
Public 37.535.4335.4835.7237.1637.3245.4145.1544.9344.88
Others 0000000000
Total 100100100100100100100100100100

Kaya Peer Comparison

Hospital & Healthcare Services Edit Columns

Kaya Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Kaya Pros & Cons

Pros

  • Stock is trading at -2.9 times its book value
  • Debtor days have improved from 763.48 to 429.39days.
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 0% over the last 3 years.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp